CONMED Corporation
CNMDHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframeCONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. Valued at $1.07B, CNMD is a small-cap name in its sector. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Market Cap
$1.07B
Beta
0.94
P/E (TTM)
20.17
P/E (Fwd)
7.37
EPS (TTM)
$1.77
EPS (Fwd)
$4.85
ROE
5.5%
ROA
3.7%
Cash
$35.0M
Total Debt
$860.9M
Free CF
$125.9M
52W Change
-35.5%
Annual Financials
Cash vs Debt
CONMED Corporation carries $860.9M in total debt against $35.0M in cash reserves — debt is roughly 24.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $125.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 5.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.05B (2022) to $1.37B (2025), reflecting a 31% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CNMD.